WITHUS PHARMACEUTICAL Co.,LTD.

KOSDAQ:A330350 Stock Report

Market Cap: ₩87.5b

WITHUS PHARMACEUTICALLTD Past Earnings Performance

Past criteria checks 4/6

WITHUS PHARMACEUTICALLTD's earnings have been declining at an average annual rate of -6%, while the Pharmaceuticals industry saw earnings growing at 7.5% annually. Revenues have been growing at an average rate of 21.8% per year. WITHUS PHARMACEUTICALLTD's return on equity is 7.3%, and it has net margins of 6.4%.

Key information

-6.0%

Earnings growth rate

-98.9%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate21.8%
Return on equity7.3%
Net Margin6.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

We Think That There Are Issues Underlying WITHUS PHARMACEUTICALLTD's (KOSDAQ:330350) Earnings

May 25
We Think That There Are Issues Underlying WITHUS PHARMACEUTICALLTD's (KOSDAQ:330350) Earnings

We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability

Dec 09
We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability

Recent updates

These 4 Measures Indicate That WITHUS PHARMACEUTICALLTD (KOSDAQ:330350) Is Using Debt Reasonably Well

Nov 13
These 4 Measures Indicate That WITHUS PHARMACEUTICALLTD (KOSDAQ:330350) Is Using Debt Reasonably Well

We Think That There Are Issues Underlying WITHUS PHARMACEUTICALLTD's (KOSDAQ:330350) Earnings

May 25
We Think That There Are Issues Underlying WITHUS PHARMACEUTICALLTD's (KOSDAQ:330350) Earnings

Here's What Withuspharmaceutical Co.,Ltd.'s (KOSDAQ:330350) Shareholder Ownership Structure Looks Like

Feb 17
Here's What Withuspharmaceutical Co.,Ltd.'s (KOSDAQ:330350) Shareholder Ownership Structure Looks Like

Calculating The Intrinsic Value Of Withuspharmaceutical Co.,Ltd. (KOSDAQ:330350)

Jan 13
Calculating The Intrinsic Value Of Withuspharmaceutical Co.,Ltd. (KOSDAQ:330350)

We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability

Dec 09
We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability

Revenue & Expenses Breakdown

How WITHUS PHARMACEUTICALLTD makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A330350 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24105,7396,72555,1062,192
30 Jun 2498,2747,65249,7372,084
31 Mar 2490,1479,19442,9221,517
31 Dec 2380,1197,95937,3471,868
30 Sep 2368,9753,26434,3992,067
30 Jun 2365,7941,60632,1122,410
31 Mar 2363,0321,05730,7422,615
31 Dec 2264,6802,47929,8492,357
30 Sep 2264,6185,42427,7972,108
30 Jun 2262,4615,28227,1361,852
31 Mar 2261,5645,08926,7541,586
31 Dec 2157,4194,26426,3281,420
31 Dec 2053,4066,65222,8071,807
30 Sep 2052,8427,07522,2291,983
30 Jun 2052,3938,03921,1501,512
31 Mar 2053,7438,74221,9741,149
30 Jun 1951,7328,66120,158587
30 Jun 1850,9458,49119,3020
30 Jun 1749,5197,33219,1120
30 Jun 1645,8787,84417,5420
30 Jun 1541,6407,14712,4400
30 Jun 1439,1926,37212,5880

Quality Earnings: A330350 has high quality earnings.

Growing Profit Margin: A330350's current net profit margins (6.4%) are higher than last year (4.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A330350's earnings have declined by 6% per year over the past 5 years.

Accelerating Growth: A330350's earnings growth over the past year (106%) exceeds its 5-year average (-6% per year).

Earnings vs Industry: A330350 earnings growth over the past year (106%) exceeded the Pharmaceuticals industry 22.3%.

Return on Equity

High ROE: A330350's Return on Equity (7.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 23:22
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

WITHUS PHARMACEUTICAL Co.,LTD. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jongsun ParkEugene Investment & Securities Co Ltd.
Hyun Dong LeeNH Investment & Securities Co., Ltd.
Kwan Jun RaNH Investment & Securities Co., Ltd.